Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Tumour immune barrier determines immunotherapy efficacy in HCC
A tumour immune barrier (TIB) structure formed by the interaction of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) appears to influence the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC), reveals a study.
Tumour immune barrier determines immunotherapy efficacy in HCC
01 Apr 2023
Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection
A recent study has found a small-molecule covalently closed circular DNA (cccDNA) inhibitor that reduces levels of hepatitis B virus (HBV) cccDNA. This discovery offers a new way to cure patients with chronic HBV infection.
Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection
31 Mar 2023
Time-restricted eating offers no additional benefits in adults with obesity, NAFLD
Time-restricted eating does not appear to be more effective than daily calorie restriction in terms of improving intrahepatic triglyceride content, body fat, and metabolic risk factors for adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to a study.
Time-restricted eating offers no additional benefits in adults with obesity, NAFLD
24 Mar 2023
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
Use of telbivudine (LdT) during the second trimester of pregnancy helps prevent mother-to-child transmission of hepatitis B virus, reveals a study. In addition, treatment with LdT during pregnancy is safe in the long term for both mothers and infants.
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
20 Mar 2023
Selgantolimod well tolerated, induces serologic changes in CHB
Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.
Selgantolimod well tolerated, induces serologic changes in CHB
09 Mar 2023
FIB-4 changes linked to risk of cirrhosis, HCC in NAFLD
Longitudinal changes in fibrosis-4 (FIB-4) score are strongly predictive of progression to cirrhosis and hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD), reveals a study.
FIB-4 changes linked to risk of cirrhosis, HCC in NAFLD
08 Mar 2023
Local plus systemic therapies improve survival in HCC
Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.